The DNA testing company, which has 10 million customers, misses nearly 90 percent of people with risky BRCA mutations. It says the criticism is overblown.
from NYT > Business https://nyti.ms/2IpGT0R
Post Top Ad
Wednesday, 17 April 2019
Don’t Count on 23andMe to Detect Most Breast Cancer Risks, Study Warns
Tags
# BUSINESS
# NYT > Business
Share This
About sdas126
NYT > Business
Labels:
BUSINESS,
NYT > Business
Subscribe to:
Post Comments (Atom)
Post Bottom Ad
Responsive Ads Here
No comments:
Post a Comment